Tuesday, 02 January 2024 12:17 GMT

Uzbekistan, China Review Plans To Expand Pharmaceutical Cooperation


(MENAFN- Trend News Agency) TASHKENT, Uzbekistan, November 22. Uzbekistan and China have discussed joint initiatives aimed at strengthening cooperation in the pharmaceutical sector, expanding local production, and developing investment projects, Trend reports via the Agency for the Development of the Pharmaceutical Industry of Uzbekistan.

The parties explored opportunities to increase the turnover of pharmaceutical products and raw materials as part of efforts to deepen industry-level collaboration.

The discussions took place during a meeting between representatives of the Agency for the Development of the Pharmaceutical Industry and a delegation from the Xinjiang Pharmaceutical Administration of the People's Republic of China, led by its Director General, Sui Yang.

Both sides expressed readiness to continue cooperation and further develop an active dialogue to implement the agreed initiatives.

Founded in 2017, the Agency for the Development of the Pharmaceutical Industry (Pharm Agency) is a government institution in Uzbekistan tasked with enhancing the nation's pharmaceutical industry. Its primary objectives encompass formulating and executing strategies to promote industry growth, enhancing the accessibility of affordable, high-quality pharmaceuticals and medical products, and overseeing their production, importation, and distribution.

Meanwhile, bilateral trade turnover between the two countries exceeded $14 billion last year, and since the beginning of 2025, it has grown by 23 percent. This steady upward trend underscores the strengthening of economic ties and reaffirms China's role as one of Uzbekistan's key and reliable partners.

MENAFN22112025000187011040ID1110381861



Trend News Agency

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search